HUTCHMED (China) (NASDAQ: HCM)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of HUTCHMED (China) (NASDAQ: HCM) through any online brokerage.
Other companies in HUTCHMED (China)’s space includes: CinCor Pharma (NASDAQ:CINC), Supernus Pharmaceuticals (NASDAQ:SUPN), Roivant Sciences (NASDAQ:ROIV), Axsome Therapeutics (NASDAQ:AXSM) and Jazz Pharmaceuticals (NASDAQ:JAZZ).
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting HCM to fall to within 12 months (a possible -71.14% downside). 50 analyst firms have reported ratings in the last year.
The stock price for HUTCHMED (China) (NASDAQ: HCM) is $13.86 last updated August 12, 2022, 8:00 PM UTC.
The next HUTCHMED (China) (HCM) dividend date is projected to be Thursday, September 1, 2022.
HUTCHMED (China)’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for HUTCHMED (China).
HUTCHMED (China) is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.